Psychemedics Corporation (PMD)
| Market Cap | 27.36M |
| Revenue (ttm) | 24.74M |
| Net Income (ttm) | -3.85M |
| Shares Out | 5.53M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $0.72 |
| Dividend Yield | 14.55% |
| Trading Day | January 15 |
| Last Price | $4.95 |
| Previous Close | $5.10 |
| Change ($) | -0.15 |
| Change (%) | -2.94% |
| Day's Open | 5.11 |
| Day's Range | 4.95 - 5.17 |
| Day's Volume | 27,587 |
| 52-Week Range | 3.67 - 10.33 |
ACTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel.
ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020.
ACTON, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020.
ACTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2020.
A New and Cost-Effective Tool to Detect and Deter Nicotine use A New and Cost-Effective Tool to Detect and Deter Nicotine use
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.
ACTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today issued a response to a Massachusetts Supreme Judicial Court ruling in the case of Boston Police De...
ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A...
Psychemedics offers a novel way for testing drug abuse.
About PMD
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual ... [Read more...]
| Industry Diagnostics & Research | Founded 1986 |
| CEO Raymond C. Kubacki | Employees 204 |
| Stock Exchange NASDAQ | Ticker Symbol PMD |
Financial Performance
In 2019, Psychemedics's revenue was $37.68 million, a decrease of -11.71% compared to the previous year's $42.67 million. Earnings were $1.54 million, a decrease of -66.36%.